These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39438602)

  • 1. Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy.
    Hicks WH; Gattie LC; Shami ME; Traylor JI; Davar D; Najjar YG; Richardson TE; McBrayer SK; Abdullah KG
    Sci Rep; 2024 Oct; 14(1):24843. PubMed ID: 39438602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy.
    Hicks WH; Gattie LC; Traylor JI; Davar D; Najjar YG; Richardson DO TE; McBrayer SK; Abdullah KG
    bioRxiv; 2024 Jan; ():. PubMed ID: 38328251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of systemic therapy in melanoma brain metastases: a narrative review.
    Saleem K; Davar D
    Chin Clin Oncol; 2022 Jun; 11(3):24. PubMed ID: 35818856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
    Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
    Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma brain metastases harboring BRAF
    Fang P; Boehling NS; Koay EJ; Bucheit AD; Jakob JA; Settle SH; Brown PD; Davies MA; Sulman EP
    J Neurooncol; 2018 Mar; 137(1):67-75. PubMed ID: 29198052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT
    Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma Brain Metastases Patient-Derived Organoids: An In Vitro Platform for Drug Screening.
    Abedellatif SE; Hosni R; Waha A; Gielen GH; Banat M; Hamed M; Güresir E; Fröhlich A; Sirokay J; Wulf AL; Kristiansen G; Pietsch T; Vatter H; Hölzel M; Schneider M; Toma MI
    Pharmaceutics; 2024 Aug; 16(8):. PubMed ID: 39204387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.
    Jablonska PA; Fong CH; Kruser T; Weiss J; Liu ZA; Takami H; Narita Y; Ynoe de Moraes F; Dasgupta A; Ong CK; Yang JCH; Lee JH; Pavlakis N; Kongkham P; Butler M; Shultz DB
    Radiother Oncol; 2022 Mar; 168():89-94. PubMed ID: 35121033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
    Babiker HM; Byron SA; Hendricks WPD; Elmquist WF; Gampa G; Vondrak J; Aldrich J; Cuyugan L; Adkins J; De Luca V; Tibes R; Borad MJ; Marceau K; Myers TJ; Paradiso LJ; Liang WS; Korn RL; Cridebring D; Von Hoff DD; Carpten JD; Craig DW; Trent JM; Gordon MS
    Invest New Drugs; 2019 Aug; 37(4):636-645. PubMed ID: 30264293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
    Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
    Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillary thyroid cancer organoids harboring BRAF
    Chen D; Su X; Zhu L; Jia H; Han B; Chen H; Liang Q; Hu C; Yang H; Liu L; Li P; Wei W; Zhao Y
    J Transl Med; 2023 Jan; 21(1):9. PubMed ID: 36624452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
    Kiniwa Y; Okuyama R
    Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF
    Porcelli L; Di Fonte R; Pierri CL; Fucci L; Saponaro C; Armenio A; Serratì S; Strippoli S; Fasano R; Volpicella M; Daprile R; Tommasi S; Ressa CM; Guida M; Azzariti A
    Pharmacol Res; 2022 Aug; 182():106323. PubMed ID: 35752358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
    Cohen JV; Sullivan RJ
    Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
    Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
    Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
    Holbrook K; Lutzky J; Davies MA; Davis JM; Glitza IC; Amaria RN; Diab A; Patel SP; Amin A; Tawbi H
    Cancer; 2020 Feb; 126(3):523-530. PubMed ID: 31658370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
    Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
    Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.